Ms. Amy Worth is an Associate Director in Clinical Operations at MacroGenics. She manages oversight of clinical trials, with a strong focus on patient engagement and diverse recruitment. Her hybrid role supports the implementation of new strategies previously unexplored at MacroGenics with ‘patient focus’ front of mind. In addition, Amy’s unique position enables her to observe the impact implementation of innovative strategies on site quality, recruitment, and retention. Amy is passionate about engaging the people most impacted by innovation [patients] into MacroGenics’ clinical development process.  Amy has had the privilege of collaborating with patient advocacy groups, like PHEN, and understands the importance of community involvement and meaningful relationships to further clinical trial diversification, education, and awareness.

Ms. Cameron Davis is an Associate Director of Clinical Trial Diversity at Merck, where she supports the development and implementation of operational activities for the diverse representation of patients in clinical trials. Cameron has 15 years of clinical research experience, health promotion and management. She has research experience dedicated to various therapeutic areas, including neuro-cerebrovascular and oncology. Cameron received a Master of Science in biotechnology from Johns Hopkins University and a Master of Health Certification in public health and policy from the University of Maryland. She has a Bachelor of Science in biology from Delaware State University.

Art Cain is the Continuing Education (CE) Director at the University of Georgia and a prostate cancer survivor who has clinical trial experience. His prostate cancer had metastasized to the bone, but he is currently doing well due to several medications received via a clinical trial, bone-strengthening drugs, and a healthy lifestyle.

He has taken part in the PANTHER trial, which combines two medicines known as abiaterone and enzalutamide to distribute among one group of White men and a second group of Black men. The trial researchers assessed the racial disparity differences and outcomes in prostate cancer.

He is also a member of Cascade United Methodist Church in Atlanta and faithful member and contributor to the Men’s Usher Board at Cascade. Cain has enjoyed running his entire life and, to this day, will still take part in running 10K races. Art Cain lives in the Atlanta, Georgia area with his wife Gwen.

As part of the Janssen Diversity, Equity, and Inclusion in Clinical Trials team, Lisa Lewis helps drive the inclusion of underserved and/or underrepresented populations in oncology clinical trials. Lisa has 25 years of experience in Oncology Preclinical Research, Early and Late Clinical Development, Clinical Operations, Medical Affairs and Public Health, and Oncology Therapeutics.

Lisa has worked directly with cancer patients and clinical trial participants at academic and community sites. She has held Director, Associate Director, Senior Clinical Scientist, Global Trial Leader, and Consultant roles at companies including Novartis Oncology, Bristol-Myers Squibb, AstraZeneca, and G1 Therapeutics.

Lisa received her BS in Biology (Pre-medicine) from Stony Brook University and MPH with a concentration in Health Informatics from New York Medical College. She is continuing her studies toward an MS in Bioethics at The Harvard Medical School Center for Bioethics in the Fall of 2023.

Kim Fookes has 29+ years of experience working in clinical research. Prior to being named the Global Head of DICT, Kim was responsible for all US clinical trial deliverables across Novartis’ portfolio, including early and late phase oncology and non-oncology.  She joined Novartis from AbbVie where she was the Head of Site Management & Monitoring, overseeing Global Site Management.  While at AbbVie, Kim also managed operations for the Global Medical Affairs’ Therapeutic Areas and US Medical Affairs.  Prior to AbbVie, she worked at Takeda, CROs, and Site Research Centers.

In her role as Global Head of DICT, she is working to imbed diversity across the R&D continuum so teams can consider diverse patient populations very early, including phase I trials.